{"filings":[{"id":1343076,"accession_number":"0001628280-26-046143","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-06-30T12:28:42+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vistagen PALISADE-4 Phase 3 Trial of Fasedienol Misses Primary Endpoint; Post-Hoc Signal in Severe Subgroup","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PALISADE-4 trial (n=238) did not meet primary endpoint: LS mean change SUDS fasedienol -9.5 vs placebo -11.4 (p=0.427).","Post-hoc analysis in very severe subgroup (LSAS >=95, n=123) showed nominal significance: fasedienol -12.8 vs placebo -3.7 (p=0.036).","Fasedienol safety and tolerability consistent with previous placebo-controlled trials.","Company plans to meet with FDA to discuss registrational pathway using a single future Phase 3 trial with LSAS as primary endpoint and confirmatory evidence from PALISADE program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1113477,"accession_number":"0001628280-26-043989","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-06-17T21:13:49+00:00","items":["5.02"],"status":"ready","headline":"Two Vistagen directors will not stand for re-election at 2026 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Margaret FitzPatrick (June 16) and Joanne Curley (June 17) notified Vistagen they will not stand for re-election.","Both will continue serving as directors until the end of their terms at the 2026 Annual Meeting.","No replacements have been announced; board composition will change after the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1057637,"accession_number":"0001628280-26-043232","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-06-15T20:35:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vistagen FY2026 net loss $69.7M; PALISADE-4 topline results expected June 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $69.7M for FY ended March 31, 2026, vs $51.4M prior year; R&D expense $55.0M.","Cash and marketable securities $45.4M; management expects runway into 2027.","Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder; topline results expected in June 2026.","Received FDA 'Study May Proceed' letter for refisolone IND for menopausal hot flashes.","Appointed new CMO (Dr. Angel Angelov), CFO (Nick Tressler), and Chief Corporate Development Officer (Elissa Cote)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":947638,"accession_number":"0001628280-26-041962","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-06-09T21:04:52+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen achieves ICH E1 safety exposure minimum for fasedienol; over 1,500 subjects dosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of May 31, 2026: over 1,500 subjects with ≥1 dose, 300 with ≥6 months, 100 with ≥12 months exposure to fasedienol.","Milestone supports safety database for NDA; FDA alignment on specific exposure requirements still pending.","Topline results from PALISADE-4 Phase 3 trial expected Q2 2026; Phase 2 Repeat Dose study topline due Q3 2026.","Fasedienol is a pherine nasal spray for acute treatment of social anxiety disorder; no new safety signals reported.","CEO notes encouraging subject participation in open-label extensions and well-tolerated profile across trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":527680,"accession_number":"0001628280-26-036492","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-05-19T20:30:03+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vistagen appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer effective May 18, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Angelov brings two decades of industry experience including roles at Karuna Therapeutics, Neurocrine Biosciences, Novartis, and Teva.","Annual base salary of $425,000, $50,000 signing bonus paid in two tranches, and eligibility for annual discretionary bonus (target 45% of salary).","Inducement grant of 150,000 stock options at $0.5955 per share, vesting over 4 years with 25% cliff at one year.","Dr. Angelov is board-certified in psychiatry and holds an MBA from Wharton; will lead clinical development for Vistagen's pherine pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22602,"accession_number":"0001628280-26-033883","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-05-12T11:44:41+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen reports positive preliminary OLE data for fasedienol in SAD; well-tolerated up to 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OLE safety (n=341): discontinuation due to AEs 2.6%; no SAEs related to fasedienol; TEAEs >5%: headache 10.9%, URI 11.4%.","LSAS mean improvement: 16.3 pts at Month 1, 25.4 pts at Month 4; 56% had >=20 pt improvement at Month 4.","SPIN mean improvement: 7.9 pts at Month 1, 12.4 pts at Month 4; 55% had >=10 pt improvement at Month 4.","Baseline LSAS mean 99.2 (very severe SAD); baseline SPIN mean 48.7 (severe); improvements seen on both fear/avoidance subscales.","Non-responders in randomized portion showed comparable LSAS improvement: Month 1 =13.4, Month 4 =20.8, 50% >=20 pts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92707,"accession_number":"0001628280-26-032935","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen completes PALISADE-4 Phase 3 patient visits; topline data due Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient completed randomized portion of Phase 3 trial for fasedienol acute treatment of social anxiety disorder.","Topline results for PALISADE-4 expected in second quarter 2026.","FDA has no comments on refined statistical analysis plan incorporating pre-dose SUDS baseline covariate.","Open-label extension remains ongoing; fasedienol has FDA Fast Track designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92706,"accession_number":"0001628280-26-027930","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen gets FDA 'Study May Proceed' letter for refisolone nasal spray in menopausal hot flashes","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA allows Vistagen to pursue further Phase 2 clinical development of refisolone in U.S. for vasomotor symptoms due to menopause.","Exploratory Phase 2a study (N=36): refisolone reduced hot flash frequency by 80% vs 36% placebo; effect seen by week 1 (p<.001).","Refisolone was well-tolerated with no serious drug-related adverse events in the Phase 2a study conducted in Mexico.","Company cites large unmet need: ~75% of women in America experience hot flashes during menopausal transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92705,"accession_number":"0001628280-26-024943","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vistagen grants 75,000-share options to CEO, CFO, and three other executives at $0.5358","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Options granted to five executives: CEO Shawn Singh, CLO Reid Adler, CDO Elissa Cote, COO Joshua Prince, CFO Nick Tressler.","Each option covers 75,000 shares; exercise price $0.5358 per share.","Vesting: 25% at 6 months, then 25% every 6 months thereafter, fully vested in 2 years.","Granted under Amended and Restated 2019 Omnibus Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92704,"accession_number":"0001628280-26-023176","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vistagen falls below Nasdaq audit committee minimum after director resignation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Ms. Mary Rotunno resigned from the Board effective April 1, 2026, reducing Audit Committee from 3 to 2 members.","Company notified Nasdaq of non-compliance with Listing Rule 5605(c)(2) requiring at least three audit committee members.","Nasdaq listing not affected; cure period of up to one year from resignation date to regain compliance.","Board plans to fill vacancy and return to compliance within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103757,"accession_number":"0001628280-26-019455","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mary Rotunno resigns from Vistagen Therapeutics board effective April 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Rotunno resigned from the Board of Directors on March 17, 2026, effective April 1, 2026.","No reason for resignation or replacement disclosed in the filing.","Resignation reported under Item 5.02; no other executive changes mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103756,"accession_number":"0001628280-26-018163","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vistagen files new corporate presentation; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed 8-K to announce use of updated corporate presentation dated March 2026.","Presentation covers pipeline and strategy but no specific financial or clinical data provided.","No earnings, guidance, or operational milestones were released in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103755,"accession_number":"0001628280-26-016652","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vistagen cuts workforce 20%, cites cash management; PALISADE-4 results expected H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced workforce by approximately 20% to prioritize fasedienol PALISADE-4 Phase 3 trial.","Topline results from PALISADE-4 for social anxiety disorder expected first half of 2026.","Company expects cash runway to extend into 2027 after the workforce reduction.","Affected employees may receive cash severance and healthcare coverage; costs expected immaterial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103754,"accession_number":"0001628280-26-010035","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vistagen Therapeutics director Paul Edick resigns; board vacancy to be filled","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Edick resigned from the Board of Directors effective February 13, 2026.","The Company is actively seeking new candidates to fill the resulting vacancy.","No reason for resignation was disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103753,"accession_number":"0001628280-26-007715","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vistagen Q3 FY2026 net loss $18.9M; PALISADE-4 topline expected H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.9M for quarter ended Dec 31, 2025, vs $14.1M a year ago; R&D expense $14.2M, G&A $5.6M.","Cash and equivalents $61.8M as of Dec 31, 2025; company targeting disciplined capital allocation.","PALISADE-4 Phase 3 trial of fasedienol for social anxiety ongoing; topline results from randomized portion expected H1 2026.","Previous PALISADE-3 Phase 3 missed primary endpoint in Dec 2025; safety data favorable.","Appointed Nick Tressler as CFO in Dec 2025; refisolone IND submission for hot flashes planned H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":804000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103752,"accession_number":"0001628280-26-006078","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vistagen receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 3, 2026 for non-compliance with $1.00 minimum bid price requirement.","Stock closed below $1.00 for 30 consecutive business days; no immediate effect on listing.","Must regain compliance by Aug 3, 2026 by having $1.00 closing bid for 10 consecutive days.","May qualify for a second 180-day compliance period if other listing standards are met.","Failure to regain compliance could result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103751,"accession_number":"0001628280-26-001690","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vistagen releases corporate presentation highlighting nose-to-brain neuroscience platform","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated January 2026 describes nose-to-brain neurocircuitry for CNS disorders.","No financial data, pipeline updates, or milestones disclosed in the filing excerpt.","VTGN common stock trades on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120016,"accession_number":"0001628280-25-058594","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vistagen's PALISADE-3 Phase 3 study of fasedienol fails primary endpoint in social anxiety disorder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LS mean change from baseline on SUDS score: fasedienol 13.6 (SE 1.54) vs placebo 14.0 (SE 1.51); no statistical significance.","Secondary endpoints also showed no treatment difference between fasedienol and placebo.","Favorable safety data consistent with prior trials; no new safety signals.","Phase 3 failure likely halts development path for intranasal fasedienol in acute social anxiety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120015,"accession_number":"0001628280-25-055083","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vistagen appoints Nick Tressler as CFO effective Dec 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nick Tressler named CFO & Treasurer, effective Dec 1, 2025; succeeds Shawn Singh as interim PFO.","Starting annual base salary of $450,000; signing bonus of $50,000; target cash bonus of 45% of base.","Granted inducement option for 150,000 shares at $4.43 per share; vests over 4 years with 1-yr cliff.","Tressler brings 20+ years life sciences finance experience; most recently CFO at DYNEX Technologies.","Shawn Singh will no longer serve as interim principal financial and accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120014,"accession_number":"0001628280-25-052077","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vistagen reports Q2 FY2026 net loss $19.4M; PALISADE-3 Phase 3 complete, topline due Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.4M vs $13.0M YoY; R&D expense $15.9M (up 56% YoY) on PALISADE program.","PALISADE-3 Phase 3 trial of fasedienol for social anxiety disorder completed; topline data expected by Q4 2025.","PALISADE-4 Phase 3 trial topline expected H1 2026; same public speaking challenge design.","Cash, equivalents, and marketable securities $77.2M as of Sep 30, 2025.","Paul Edick appointed to board of directors, effective October 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":502000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120013,"accession_number":"0001628280-25-048827","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vistagen completes PALISADE-3 Phase 3 trial; topline results due by year end","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient completed randomized, double-blind, placebo-controlled portion of PALISADE-3 for fasedienol in social anxiety disorder; open-label extension ongoing.","Topline results for PALISADE-3 expected in Q4 2025; PALISADE-4 topline anticipated in H1 2026.","PALISADE-3 uses same design as positive PALISADE-2 trial (SUDS primary endpoint); FDA Fast Track designation in place.","Successful PALISADE-3 or -4 could support NDA submission for first acute treatment for social anxiety disorder (over 30M patients)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120012,"accession_number":"0001628280-25-047188","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vistagen appoints Paul Edick to Board of Directors, effective October 27, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Edick appointed to Board, Audit Committee, and Compensation Committee.","Received options to purchase 35,200 shares at $3.90/share (closing price on appointment date), vesting over 3 years.","He is entitled to annual cash and equity compensation under the Director Compensation Plan.","Mr. Edick is former Chairman/CEO of Xeris Pharmaceuticals and ex-CEO of Durata Therapeutics.","No family relationships or transactions with the company requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136577,"accession_number":"0001411685-25-000081","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Vistagen CFO Cynthia Anderson resigns effective Oct 15; annual meeting votes ratified","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Cynthia L. Anderson resigns effective Oct 15, 2025; resignation not due to any disagreement with company.","Company is searching for a successor; intends to enter a consulting agreement with Anderson for transition support.","Six director nominees elected at annual meeting, including CEO Shawn Singh and Chair Margaret FitzPatrick.","Non-binding advisory vote on executive compensation (say-on-pay) approved by stockholders.","Appointment of KPMG as independent auditor for fiscal year ending March 31, 2026 ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136576,"accession_number":"0001411685-25-000062","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vistagen reports Q1 net loss of $15.1M; fasedienol Phase 3 data expected Q4 2025 and H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.1M for fiscal Q1 ended June 30, 2025, vs $10.7M a year ago; R&D expense up to $11.7M.","Cash, cash equivalents, and marketable securities at $63.2M as of June 30, 2025.","Topline data from PALISADE-3 Phase 3 trial of fasedienol (SAD) expected Q4 2025; PALISADE-4 data H1 2026.","PH80 for menopausal hot flashes – IND preparation underway for further Phase 2 development.","Appointed Elissa Cote as Chief Corporate Development Officer in June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":244000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153766,"accession_number":"0001411685-25-000048","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vistagen appoints Elissa Cote as Chief Corporate Development Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cote appointed CCDO effective June 23, 2025, to lead strategic partnerships and pherine platform advancement.","Nearly 30 years biopharma BD experience; previously Chief Strategy/BD Officer at Mallinckrodt Pharmaceuticals.","Received inducement option for 150,000 shares at June 23 closing price; vests 25% year one, then monthly over 36 months.","Pipeline includes five intranasal pherine candidates targeting six CNS disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153765,"accession_number":"0001411685-25-000046","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Vistagen reports FY2025 net loss $51.4M; cash $80.5M; advances PALISADE fasedienol trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2025 net loss $51.4M (vs $29.4M prior year); R&D expenses doubled to $39.4M on fasedienol and PH80 programs.","Cash, cash equivalents and marketable securities $80.5M as of March 31, 2025.","PALISADE-3 fasedienol topline results expected Q4 2025; PALISADE-4 results expected H1 2026.","Filed prospectus supplement to sell up to $175M common stock via ATM (replacing $100M prior); ~$3.4M already sold.","Itruvone for MDD planning further Phase 2; PH80 for menopausal hot flashes preparing U.S. IND."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153764,"accession_number":"0001411685-25-000028","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vistagen updates fasedienol Phase 3 timelines: PALISADE-3 data Q4 2025, PALISADE-4 H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PALISADE-3 topline data remains on track for Q4 2025; PALISADE-4 now expected in H1 2026.","Positive PALISADE-2 results (2023) plus success in either PALISADE-3 or -4 could support NDA submission.","Protocol enhancements include site training, surveillance, and subject selection to replicate PALISADE-2 success.","CEO cites strong patient/physician enthusiasm and growing unmet need in social anxiety disorder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172450,"accession_number":"0001411685-25-000023","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen sued by pro se plaintiffs over alleged misleading clinical trial disclosures","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["John Cesario and David Preka filed lawsuit on Feb 13, 2025 (Case No. 4:25-cv-01510) in Northern District of California.","Complaint alleges violations of Sections 10(b), Rule 10b-5, Sections 11 and 17(a) over public disclosures on clinical trials.","Plaintiffs seek compensatory, punitive damages, fees, and costs.","Vistagen believes allegations are wholly without merit and intends to defend vigorously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172449,"accession_number":"0001411685-25-000017","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vistagen reports Q3 FY2025 net loss $14.1M; fasedienol Phase 3 progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.1M for Q3 ended Dec 31, 2024, vs $6.4M YoY; R&D expense rose to $11.3M from $4.5M.","Cash and marketable securities $88.6M as of Dec 31, 2024.","Fasedienol PALISADE-3 and PALISADE-4 Phase 3 trials for SAD ongoing; top-line results expected later 2025.","Positive exploratory Phase 2A results for PH284 in cancer cachexia announced.","IND-enabling program for PH80 for menopausal hot flashes continuing; Phase 2B planning for itruvone in MDD."],"consensus_eps_estimate":-0.4855,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":501000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172448,"accession_number":"0001411685-25-000011","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen receives US patent for AV-101 to treat neuropathic pain; patent exp. 2034","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO granted patent for oral non-opioid AV-101 covering neuropathic pain, expiring at least 2034.","Patent strengthens IP for AV-101 targeting disorders involving NMDA receptor, including pain and dyskinesias.","Preclinical data showed AV-101 similar efficacy to gabapentin/pregabalin with better side effect profile.","Phase 1 data in Journal of Pain indicated AV-101 well tolerated; allodynia/hyperalgesia reductions observed.","Vistagen plans to seek strategic partnerships for AV-101 development and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172447,"accession_number":"0001411685-25-000007","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen announces positive Phase 2A results for PH284 in cancer cachexia; 71% hunger improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PH284 nasal spray demonstrated 71% improvement in subjective feeling of hunger before dinner on Day 7 vs <1% for placebo.","No serious adverse events; adverse events similar to placebo and attributed to underlying cancer, not treatment.","PH284 is fifth pherine product candidate in Vistagen's neuroscience pipeline with a positive efficacy signal.","Study enrolled 40 female patients with cachexia due to terminal cancer; double-blind, placebo-controlled design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172446,"accession_number":"0001411685-25-000004","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen enrolls first subject in fasedienol repeat dose study for social anxiety disorder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 exploratory trial evaluating repeat dose of fasedienol (3.2 mcg) in adults with SAD during a public speaking challenge.","Three arms: fasedienol+fasedienol (total 6.4 mcg), fasedienol+placebo (3.2 mcg), placebo+placebo; second dose 10 min after initial.","Study design mirrors ongoing PALISADE Phase 3 program including open-label extension.","CEO notes no FDA-approved acute treatment option exists for SAD despite high prevalence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189442,"accession_number":"0001411685-24-000059","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vistagen posts new corporate presentation; no specific financial updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company released an updated corporate presentation on December 6, 2024.","Tagline: 'Pioneering neuroscience with nose-to-brain neurocircuitry'.","No new financial guidance, clinical results, or material transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189441,"accession_number":"0001411685-24-000051","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vistagen Q2 FY2025 net loss $13.0M; Phase 3 SAD trials on track for 2025 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.0M for Q2 ended Sep 30, 2024 vs $6.6M a year ago, driven by higher R&D costs.","R&D expense $10.2M (up from $3.9M) due to fasedienol PALISADE Phase 3 program costs.","Cash, cash equivalents and marketable securities $97.6M as of Sep 30, 2024.","PALISADE-3 and PALISADE-4 Phase 3 trials for fasedienol in social anxiety disorder actively recruiting; top-line results expected in 2025.","Itruvone Phase 2B prep for MDD and PH80 IND-enabling program for menopausal hot flashes ongoing."],"consensus_eps_estimate":-0.4828,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":267000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205955,"accession_number":"0001411685-24-000042","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen enrolls first subject in PALISADE-4 Phase 3 trial of fasedienol for SAD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First subject enrolled in PALISADE-4 Phase 3 trial of fasedienol nasal spray for acute treatment of social anxiety disorder (SAD).","Fasedienol is an investigational neuroactive pherine candidate in U.S. registration-directed Phase 3 development.","Over 30 million Americans suffer from SAD; no FDA-approved acute treatments currently available.","Fasedienol targets nose-to-brain neural circuits to reduce fear and anxiety associated with SAD.","CEO Shawn Singh confirmed the milestone was achieved as planned in the registration-directed program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205954,"accession_number":"0001437749-24-027943","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vistagen stockholders elect all seven director nominees, approve say-on-pay, ratify auditors at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected, including CEO Shawn K. Singh with 14,540,841 votes for and 154,427 withheld.","Non-binding advisory vote on executive compensation approved: 13,758,902 for, 842,393 against, 93,973 abstain.","Ratification of KPMG LLP as independent auditor for FY2025 overwhelmingly approved: 21,277,275 for, 49,205 against.","Meeting held August 26, 2024; results reported in 8-K filed August 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205953,"accession_number":"0001411685-24-000039","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vistagen Q1 FY2025 net loss $10.7M; PALISADE Phase 3 trials on track for 2025 results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.7M for Q1 FY2025, up from $6.9M in Q1 FY2024.","Cash, cash equivalents, and marketable securities at $108.4M as of June 30, 2024.","PALISADE-3 Phase 3 trial for fasedienol in SAD on track for top-line results in 2025.","PALISADE-4 Phase 3 trial preparation ongoing; initiation planned H2 2024.","R&D expenses increased to $7.6M from $4.2M due to PALISADE trial costs."],"consensus_eps_estimate":-0.5066,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":84000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205952,"accession_number":"0001437749-24-022667","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Vistagen dismisses WithumSmith+Brown, appoints KPMG as new auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dismissed WithumSmith+Brown, PC as auditor effective July 8, 2024, after competitive selection process by Audit Committee.","No disagreements or reportable events between Company and Withum for fiscal years ended March 31, 2024 and 2023.","Withum's 2023 audit report included going concern paragraph; 2024 report did not.","Engaged KPMG LLP as new independent registered public accounting firm for fiscal year ending March 31, 2025.","No prior consultations with KPMG on accounting principles, disagreements, or reportable events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205951,"accession_number":"0001437749-24-022484","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen expands PH80 global patent portfolio with new migraine treatment patents in four countries","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New patents for PH80 migraine treatment issued/allowed in Australia, Hong Kong, Japan, and Mexico.","All new patents expected to be in effect until 2040, subject to possible term extensions.","PH80 is a non-systemic, hormone-free investigational pherine nasal spray for menopausal hot flashes and other conditions.","Patents complement previously granted U.S. Patent No. 11,419,881 and EPO Patent No. 3955933 for migraine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222970,"accession_number":"0001437749-24-021626","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen awarded MHA Platinum Bell Seal for Workplace Mental Health for 2nd year","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Received Mental Health America's highest honor, Platinum Bell Seal, for second consecutive year.","Award recognizes Vistagen's supportive workplace culture, mental health benefits, and employee wellness programs.","CEO Shawn Singh highlighted normalizing mental health conversations and supporting employees.","Announced June 27, 2024 via press release filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222969,"accession_number":"0001411685-24-000023","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vistagen FY2024 net loss narrows to $29.4M; fasedienol Phase 3 program on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.4M for FY2024, down from $59.2M in FY2023; cash and equivalents $119.2M as of March 31, 2024.","R&D expenses decreased to $20.0M from $44.4M, primarily due to timing of fasedienol Phase 3 trials.","PALISADE-3 Phase 3 trial for fasedienol in SAD initiated; PALISADE-4 expected in 2H 2024; positive PALISADE-2 results previously.","Appointed Cindy Anderson as CFO; entered exclusive negotiation with Fuji Pharma to develop PH80 in Japan for menopausal hot flashes.","Completed underwritten public offering to fund pipeline milestones; itruvone Phase 2B planning underway for MDD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222968,"accession_number":"0001437749-24-018902","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vistagen stockholders approve major increase in authorized equity shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved amendment to 2019 Omnibus Equity Incentive Plan: authorized shares increase from 1M to 5M; 82.0% votes cast in favor.","Approved amendment to 2019 Employee Stock Purchase Plan: authorized shares increase from 33,334 to 1M; 82.3% votes cast in favor.","Both proposals passed at special meeting held May 29, 2024, with over 82% of votes cast supporting each.","Total potential dilution from the two plan amendments increases available shares by 4.97M (net of prior reserves)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222967,"accession_number":"0001437749-24-018214","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen to present fasedienol and itruvone data at ASCP conference May 28-31","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster on fasedienol (Phase 3 for social anxiety disorder) from PALISADE-2 trial on May 29.","Poster on intranasal itruvone (Phase 2 for major depressive disorder) distribution in rats on May 29.","Posters will be available on Vistagen website on June 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222966,"accession_number":"0001437749-24-013283","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen announces positive Phase 2A results for PH15 nasal spray improving psychomotor impairment from mental fatigue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PH15 nasal spray demonstrated statistically significant improvement in reaction time versus placebo and caffeine (p<0.001) in sleep-deprived participants.","Phase 2A pilot study (2011, acquired via Pherin in February 2023) enrolled 10 participants in a crossover design.","PH15 was safe and well-tolerated; adverse events comparable to placebo, with brief nasal itching in one subject.","CEO Shawn Singh highlighted potential for shift work disorder, sleep apnea, and narcolepsy patients.","No serious adverse events reported; caffeine group experienced palpitations, euphoria, dry mouth, stomachache, and polyuria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222965,"accession_number":"0001437749-24-010427","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen enrolls first patient in PALISADE-3 Phase 3 fasedienol trial for social anxiety disorder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PALISADE-3 is a randomized, double-blind, placebo-controlled study of ~236 adults aged 18–65 with SAD.","Primary endpoint is patient-rated SUDS; patients randomized 1:1 to fasedienol or placebo.","Follows positive PALISADE-2 results; PALISADE-4 replication planned for H2 2024.","Social anxiety disorder affects over 25 million Americans; fasedienol is an investigational pherine.","CEO Shawn Singh calls the initiation a 'major milestone' toward first-in-class treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242456,"accession_number":"0001437749-24-003924","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vistagen reports narrower net loss of $6.3M in fiscal Q3; fasedienol trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.3M vs $9.8M YoY; cash $126.6M at Dec 31, 2023.","R&D expense $4.5M, down from $6.9M on lower clinical costs.","G&A expense $3.8M, up from $3.1M on compensation.","PALISADE-3 fasedienol trial for SAD initiation expected 1H 2024; PALISADE-4 in 2H 2024.","Preparations underway for itruvone Phase 2B in MDD and PH80 Phase 2B in vasomotor symptoms."],"consensus_eps_estimate":-0.4855,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":866700.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242455,"accession_number":"0001437749-24-000902","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vistagen begins using updated corporate presentation on January 8, 2024","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["New corporate presentation adopted by Vistagen Therapeutics on Jan 8, 2024.","Presentation attached as Exhibit 99.1; no financial or pipeline details provided in the filing.","Item 7.01 disclosure; information is furnished, not filed, under SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242454,"accession_number":"0001437749-24-000419","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen receives EPO notice of intention to grant AV-101 patent for neuropathic pain","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Patent Office issued Notice of Intention to Grant patent for AV-101 to treat neuropathic pain.","Patent will not expire until at least 2034; adds to global AV-101 portfolio.","Preclinical data show AV-101 similar efficacy to gabapentin and pregabalin with better side effect profile.","Phase 1 data demonstrate AV-101 well-tolerated with no meaningful difference vs placebo.","Vistagen plans to seek strategic collaborations to advance AV-101 development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259851,"accession_number":"0001437749-23-031291","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vistagen reports Q2 net loss $6.6M; fasedienol PALISADE-2 positive; cash $37.6M + $93.5M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.6M for Q2 end Sep 30, 2023 vs $17.5M YoY; R&D expense decreased to $3.9M.","Cash $37.6M at Sep 30; raised $93.5M net from public offering plus $1.5M from Fuji Pharma.","Fasedienol PALISADE-2 Phase 3 met primary and secondary endpoints; PALISADE-3 and -4 planned 2024; NDA target 1H 2026.","Itruvone Phase 2B for MDD and PH80 Phase 2B for hot flashes expected 2H 2024; PH80 positive Phase 2A in PMDD."],"consensus_eps_estimate":-0.4828,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":455300.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259846,"accession_number":"0001437749-23-030460","cik":1411685,"company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","form_type":"8-K/A","filed_at":"2023-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vistagen receives $1.5M from Fuji Pharma for exclusive PH80 negotiation in Japan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $1.5M non-refundable payment from Fuji Pharma for exclusive negotiation rights to license PH80 in Japan.","PH80 is a non-systemic, hormone-free pherine nasal spray for acute treatment of moderate-to-severe hot flashes due to menopause.","Purchase price credited against signing fee if definitive license agreement reached.","Neither party obligated to enter definitive agreement; negotiations may be terminated after exclusive period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24960000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-11-07T23:59:59+00:00|259846"}